LeJeune Puetz Investment Counsel LLC lifted its holdings in Becton Dickinson and Co (NYSE:BDX) by 4.4% during the third quarter, HoldingsChannel.com reports. The firm owned 5,980 shares of the medical instruments supplier’s stock after purchasing an additional 250 shares during the period. LeJeune Puetz Investment Counsel LLC’s holdings in Becton Dickinson and were worth $1,513,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in BDX. Bath Savings Trust Co lifted its position in Becton Dickinson and by 12.5% in the 2nd quarter. Bath Savings Trust Co now owns 27,899 shares of the medical instruments supplier’s stock worth $7,031,000 after buying an additional 3,107 shares in the last quarter. Thomasville National Bank increased its stake in shares of Becton Dickinson and by 5.3% during the 2nd quarter. Thomasville National Bank now owns 1,667 shares of the medical instruments supplier’s stock worth $420,000 after purchasing an additional 84 shares during the last quarter. Baystate Wealth Management LLC increased its stake in shares of Becton Dickinson and by 39.0% during the 2nd quarter. Baystate Wealth Management LLC now owns 449 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 126 shares during the last quarter. Private Asset Management Inc. increased its stake in shares of Becton Dickinson and by 2.0% during the 2nd quarter. Private Asset Management Inc. now owns 2,532 shares of the medical instruments supplier’s stock worth $638,000 after purchasing an additional 50 shares during the last quarter. Finally, Summit Financial Group Inc. acquired a new position in shares of Becton Dickinson and during the 2nd quarter worth $208,000. 84.26% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The disclosure for this sale can be found here. Insiders have sold a total of 37,249 shares of company stock valued at $9,616,803 over the last three months. 0.12% of the stock is currently owned by insiders.
Shares of NYSE:BDX traded down $4.75 during midday trading on Thursday, reaching $246.85. 33,501 shares of the company’s stock were exchanged, compared to its average volume of 890,069. The company’s 50 day simple moving average is $254.35 and its two-hundred day simple moving average is $246.27. The firm has a market capitalization of $67.56 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 1.60 and a beta of 1.12. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $264.74. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same period last year, the firm posted $2.91 EPS. The firm’s quarterly revenue was up 1.7% on a year-over-year basis. On average, research analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: How does new data get added to a blockchain?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.